Immunomic Therapeutics Announces Promotion of Dr. Tim Coleman to Senior Vice President, Operations and General Manager

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the promotion of Dr. Tim Coleman to the newly created role of Senior Vice President, Operations and General Manager.

Dr. Coleman joined ITI in 2015, and during his tenure with the company, has played a key role in managing several functional areas including operations, process development, facilities and IT. In particular, Dr. Coleman has successfully managed the manufacturing activities of ITI’s lead candidates with strategic partners like Astellas Pharma (“Astellas”) and CMOs like VGXI, Aldevron and Hitachi Chemical Advanced Therapeutic Solutions (“HCATS”). In his new role, Dr. Coleman will broaden his scope of responsibilities in these areas and will continue to be a contributing member of the executive leadership team.

“Tim has dedicated the last five plus years to building and growing ITI and we are thrilled to have him step into an expanded role as Senior Vice President and General Manager. His proven ability to deliver results, combined with his in-depth knowledge of our science, partnerships and company culture, will be invaluable to us as we transition into the next phase of our growth,” said William G. Hearl, CEO of Immunomic Therapeutics. “ITI is on a very positive trajectory and we look forward to building upon this momentum with Tim taking a larger role.”

Prior to joining ITI, Dr. Coleman served as Senior Director of New Product Development at SeraCare Life Sciences in Gaithersburg, MD. Dr. (Read more…) Coleman also held leadership roles at Lonza Bioscience, Inc. where he oversaw product development and quality control departments as well as Human Genome Sciences where he helped establish the Protein Development department. Dr. Coleman has authored more than 40 publications and 26 issued patents. He obtained his B.A. degree from Rutgers University in Newark, New Jersey and a Ph.D. in Molecular and Cellular Biology from Ohio University.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. ITI’s UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.

Contacts

Company Contact:
Sia Anagnostou

[email protected]
717-327-1822

Media Contact:
Amy Conrad

Juniper Point

[email protected]
858-366-3243